These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26097789)

  • 21. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
    Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
    D'Urzo A; Karpel JP; Busse WW; Boulet LP; Monahan ME; Lutsky B; Staudinger H
    Curr Med Res Opin; 2005 Aug; 21(8):1281-9. PubMed ID: 16083538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
    Nakahara N; Wakamatsu A; Kempsford R; Allen A; Yamada M; Nohda S; Hirama T
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):660-71. PubMed ID: 23735179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.
    Feldman G; Siler T; Prasad N; Jack D; Piggott S; Owen R; Higgins M; Kramer B;
    BMC Pulm Med; 2010 Mar; 10():11. PubMed ID: 20211002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of high-dose budesonide/formoterol via Turbuhaler® in Japanese patients with asthma: a randomized, double-blind, crossover, active comparator-controlled, phase III study.
    Saito T; Hasunuma T
    Clin Drug Investig; 2012 Jan; 32(1):51-61. PubMed ID: 22024920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.
    LaForce C; Alexander M; Deckelmann R; Fabbri LM; Aisanov Z; Cameron R; Owen R; Higgins M
    Allergy; 2008 Jan; 63(1):103-11. PubMed ID: 18053019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
    Busse WW; Bleecker ER; Bateman ED; Lötvall J; Forth R; Davis AM; Jacques L; Haumann B; Woodcock A
    Thorax; 2012 Jan; 67(1):35-41. PubMed ID: 21828231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma.
    Nayak AS; Banov C; Corren J; Feinstein BK; Floreani A; Friedman BF; Goldsobel A; Gottschlich GM; Hannaway PJ; Lampl KL; Lapidus RJ; Lawrence M; Lumry W; Munk Z; Pearlman D; Scardella AT; Schenkel EJ; Segal AT; Segall N; Silverman B; Shneyer L; Nolop KB; Harrison JE
    Ann Allergy Asthma Immunol; 2000 Apr; 84(4):417-24. PubMed ID: 10795650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.
    Kemp JP; Berkowitz RB; Miller SD; Murray JJ; Nolop K; Harrison JE
    J Allergy Clin Immunol; 2000 Sep; 106(3):485-92. PubMed ID: 10984368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.
    Agersø H; Jensen LB; Elbrønd B; Rolan P; Zdravkovic M
    Diabetologia; 2002 Feb; 45(2):195-202. PubMed ID: 11935150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma.
    Korenblat PE; Rosenwasser LJ
    Allergy Asthma Proc; 2010; 31(3):190-202. PubMed ID: 20482961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma.
    Corren J; Berkowitz R; Murray JJ; Prenner B
    Int J Clin Pract; 2003 Sep; 57(7):567-72. PubMed ID: 14529054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of inhaled budesonide in children in the Steroid Treatment As Regular Therapy in early asthma (START) trial.
    Silverman M; Sheffer AL; Díaz PV; Lindberg B
    Pediatr Allergy Immunol; 2006 May; 17 Suppl 17():14-20. PubMed ID: 16573704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
    Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
    PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma.
    LaForce CF; Pearlman DS; Ruff ME; Silvers WS; Weinstein SW; Clements DS; Brown A; Duke S; Harding SM; House KW
    Ann Allergy Asthma Immunol; 2000 Nov; 85(5):407-15. PubMed ID: 11101186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.